Related Experiment Video

Updated: Jan 5, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

18.7K

Aberrant signal transduction in Indian triple-negative breast cancer patients

Vasantha Kumar Bhaskara1, Chaitra Jayaram1, M Priyanga1

  • 1Department of Biochemistry, RCASC, Bengaluru, Karnataka, India.

Journal of Cancer Research and Therapeutics
|October 12, 2019
PubMed
Abstract

Insights

This study found a link between CD133 and cancer stemness pathways in Indian triple-negative breast cancer (TNBC) patients. These findings suggest CD133 may play a role in TNBC

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Triple-negative breast cancer (TNBC) is an aggressive subtype lacking standard therapeutic targets.
  • Cancer stemness, characterized by markers like CD133, is implicated in tumor recurrence and metastasis.
  • Understanding stemness pathways in TNBC is crucial for developing targeted therapies.

Purpose of the Study:

  • To investigate the association between prominin-1 (CD133) and cancer stemness pathway markers in Indian TNBC patient samples.
  • To correlate CD133 expression levels with key signaling pathways involved in stem cell maintenance.

Main Methods:

  • Immunohistochemical analysis confirmed TNBC status by assessing hormone receptor and HER2/neu (CD340) expression.
  • Total RNA was extracted from formalin-fixed paraffin-embedded TNBC tissues.
  • One-step reverse transcription-polymerase chain reaction (RT-PCR) quantified cancer stemness-related transcript levels.
  • Semi-quantitative analysis of RT-PCR products using densitometry on agarose gels.

Main Results:

  • TNBC samples exhibited significantly higher CD133 transcript levels compared to control tissues.
  • Elevated CD133 transcripts positively correlated with increased levels of NOTCH1, FZD7, transforming growth factor-beta receptor Type III R, and patched-1 pathway mediators.

Conclusions:

  • A significant correlation exists between CD133 expression and functional pathways regulating cancer stem cells in TNBC.
  • These findings highlight the potential role of CD133 in driving TNBC malignancy and suggest it as a therapeutic target.
Keywords:
Cancer stem cellsFZD7NOTCH1patched-1signal transductiontransforming growth factor-beta receptor Type III Rtriple-negative breast cancer

More Related Videos

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.2K
Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

14.1K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.2K